NCT00379912View on ClinicalTrials.gov

Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Azacitidine

Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.

DRUG

Erythropoietin

Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy

DRUG

Azacitidine (Monotherapy)

Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.

Trial Locations (9)

46202

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

46601

Northern Indiana Cancer Research Consortium, South Bend

47303

Medical Consultants, P.C., Muncie

47904

Arnett Cancer Care, Lafayette

47905

Horizon Oncology Center, Lafayette

49201

Center for Hematology-Oncology of S Michigan, Jackson

61401

Medical & Surgical Specialists, LLC, Galesburg

68114

Methodist Cancer Center, Omaha

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Ortho Biotech Clinical Affairs, L.L.C.

INDUSTRY

collaborator

Walther Cancer Institute

OTHER

lead

Larry Cripe, MD

OTHER

NCT00379912 - Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter